Teneliximab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | CD40 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
  (what is this?) (verify) | |
Teneliximab is a chimeric monoclonal antibody[1] binding to the immune stimulatory protein CD40.[2] As of 2009, it has not entered clinical trials.[2]
References
- ↑ International Nonproprietary Names For Pharmaceutical Substances
- 1 2 Law CL, Grewal IS (2009). "Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges". Advances in Experimental Medicine and Biology. New York, N.Y.: Springer Science+Business Media. 647: 8–36. doi:10.1007/978-0-387-89520-8_2. ISBN 978-0-387-89520-8. PMID 19760064.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.